PCI Biotech Holding ASA
OSE:PCIB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PCI Biotech Holding ASA
Net Income (Common)
PCI Biotech Holding ASA
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PCI Biotech Holding ASA
OSE:PCIB
|
Net Income (Common)
-kr20.5m
|
CAGR 3-Years
38%
|
CAGR 5-Years
20%
|
CAGR 10-Years
5%
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Net Income (Common)
-kr94.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Net Income (Common)
kr9.9m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Net Income (Common)
-$12.2m
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Net Income (Common)
-kr9.2m
|
CAGR 3-Years
56%
|
CAGR 5-Years
40%
|
CAGR 10-Years
14%
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Net Income (Common)
-kr58m
|
CAGR 3-Years
49%
|
CAGR 5-Years
33%
|
CAGR 10-Years
1%
|
|
PCI Biotech Holding ASA
Glance View
PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo. The company went IPO on 2008-06-18. Its activities are focused on the commercialization of a patented photochemical drug delivery technology for use in the localized cancer treatment. The Company’s products are based on the Photochemical Internalization (PCI) technology for light-directed drug delivery, used to enhance the effect of drugs by targeted illumination of the diseased areas of the body. The company focuses primarily on the drug candidate Amphinex, developed for treatment of head and neck cancer and bile duct cancer, as well as on the development of PCI for vaccination. As of December 31, 2011, it had a wholly owned subsidiary PCI Biotech AS and an affiliate PCIO Biotech Utibu, located in Iceland.
See Also
What is PCI Biotech Holding ASA's Net Income (Common)?
Net Income (Common)
-20.5m
NOK
Based on the financial report for Jun 30, 2025, PCI Biotech Holding ASA's Net Income (Common) amounts to -20.5m NOK.
What is PCI Biotech Holding ASA's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
5%
Over the last year, the Net Income (Common) growth was 26%. The average annual Net Income (Common) growth rates for PCI Biotech Holding ASA have been 38% over the past three years , 20% over the past five years , and 5% over the past ten years .
